Publications by authors named "Jozef Ampe"
Article Synopsis
- Robotic surgery is becoming more popular for pelvic floor reconstruction, but it's unclear if it's better than traditional methods, so this study aimed to clarify its role using expert opinions.* -
- An international group of 26 experienced surgeons from various specialties conducted a two-round Delphi process to evaluate the use of robotics in pelvic floor surgeries, discussing numerous aspects from surgeon characteristics to future implications.* -
- The consensus among experts was that robotic surgery offers significant technical advantages and is safe and effective for pelvic floor reconstruction, with the increased costs justified by improved surgical effectiveness.*
Obturator nerve entrapment is a rare complication after pelvic surgery and is caused by a direct intraoperative injury or secondary to compression by a postoperative collection. We have presented the case of a 65-year-old man who had complained of right-sided medial groin pain 4 weeks after robot-assisted laparoscopic prostatectomy with bilateral pelvic lymphadenectomy. Pelvic magnetic resonance imaging showed bilateral lymphoceles with right-sided compression of the obturator nerve causing diffuse muscle edema in its innervation region.
View Article and Find Full Text PDFBackground: There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potential to cost-efficiently accelerate precision medicine trials to improve clinical efficacy and diminish costs and toxicity. However, comprehensive ctDNA profiling in metastatic prostate cancer to date has been limited.
View Article and Find Full Text PDFPurpose: To infer the prognostic value of simultaneous androgen receptor () and profiling in liquid biopsies from patients with metastatic castration-resistant prostate cancer (mCRPC) starting a new line of signaling inhibitors (ARSi). Between March 2014 and April 2017, we recruited patients with mCRPC ( = 168) prior to ARSi in a cohort study encompassing 10 European centers. Blood samples were collected for comprehensive profiling of CellSearch-enriched circulating tumor cells (CTC) and circulating tumor DNA (ctDNA).
View Article and Find Full Text PDFBackground: The outcome to treatment administered to patients with metastatic castration-resistant prostate cancer (mCRPC) greatly differs between individuals, underlining the need for biomarkers guiding treatment decision making.
Objective: To investigate the prognostic value of circulating tumor cell (CTC) enumeration and dynamics, in the context of second-line endocrine therapies (ie, abiraterone acetate or enzalutamide), irrespective of prior systemic therapies.
Design, Settings, And Participants: In a prospective, multicentre study blood samples for CTC enumeration were collected from patients with mCRPC at baseline (n = 174).